15 hours ago
Chinese Biotech Showcases Challenger to Eli Lilly's Obesity Drug
An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new challenger to blockbusters from Novo Nordisk A/S and Eli Lilly & Co.
Hangzhou Sciwind Biosciences Co. said its drug, ecnoglutide, led to more than 15% weight loss after 48 weeks when given at the highest dose. Although the trial did not compare ecnoglutide directly with existing medicines, the results were very similar to what Lilly's Zepbound showed in previous China studies, Sciwind Chief Executive Officer Hai Pan said in an interview.
